Compare AbCellera Biologics Inc (ABCL) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Plby Group Inc — how do they compare? AbCellera Biologics Inc trades at $9.99 (market cap $2.99B), while Plby Group Inc trades at $1.28 (market cap $162.94M). The key difference: AbCellera Biologics Inc is far larger — about 18.4× Plby Group Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | PLBY | |
|---|---|---|
Market Cap | $2.99B | $162.94M |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $2.71 |
52-Week Low | $2.78 | $1.11 |
Enterprise Value | $2.58B | $308.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
PLBY trades at $1.18, down 3.28% recently, with a bearish technical signal. The company reported Q2 2026 revenue growth and positive operating cash flow, with net income turning positive in 2026 after years of losses. Valuation ratios like P/E of 68 and P/S of 1.2 appear elevated relative to profitability. Recent news highlights inclusion in Russell indexes and leadership expansion.
The outlook is cautiously optimistic with improving fundamentals, but high debt and thin margins pose risks. Analyst consensus is strongly bullish with 75% buy ratings, yet the stock faces execution risks in licensing growth and competitive pressures in the leisure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
